The combination of antiangiogenic therapy and cytotoxic chemotherapy is active and well tolerated in patients with sarcomatoid and poor-risk renal cell carcinoma (RCC), a recent study published online this week in the journal Cancer has shown. This single-arm, phase 2 trial evaluated the activity of sunitinib and gemcitabine combination in 39 patients with sarcomatoid RCC […]

linicians now have a better picture of what may be the optimal first-line therapy for patients with metastatic non-clear cell renal cell carcinoma (NC-RCC), according to results from a randomized phase 2 international trial of everolimus compared with sunitinib. Investigators reported at the 2015 American Society of Clinical Oncology Annual Meeting that sunitinib was superior […]